UNSPSC 51382305: Tolfenamic acid

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H12ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3G943U18KM, chemically known as benzoic acid, 2-((3-chloro-2-methylphenyl)amino)- (9ci) but generally known as tolfenamic acid, which bears US NIH Compound Identifier 5507. European Medicines Agency schedules Tolfenamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11155MIG.

UNSPSC 51382305 Tolfenamic acid is a Commodity code that in practice encompasses state and local procurement of pharmaceutical products, including naloxone, generic multi-source medications, and over-the-counter drugs distributed through community health systems and state health benefit programs. State and local governments purchasing under this code span county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that distribute pharmaceuticals to public facilities, employee health plans, and community health initiatives. The work involves competitive bidding for pharmaceutical supply contracts with quarterly or ongoing delivery requirements, compliance with Drug Supply Chain Security Act standards and current Good Manufacturing Practices certification, and fulfillment through authorized wholesale distributors.

Activity under this code is geographically distributed across Florida, Texas, and Minnesota in recent solicitations. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly deliveries to the county community health building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer pharmacy benefit program serving state employee health plans and self-insured group plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract awards effective July 1, 2026. Vendors must maintain insurance coverage including commercial general liability of at least $5,000,000 per occurrence and comply with administrative fees ranging from 3 percent to performance penalties of $200 to $1,500 per violation.